| 000 | 01695 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516233726.0 | ||
| 264 | 0 | _c20141113 | |
| 008 | 201411s 0 0 eng d | ||
| 022 | _a1471-2334 | ||
| 024 | 7 |
_a10.1186/1471-2334-14-S5-S4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOdolini, Silvia | |
| 245 | 0 | 0 |
_aSustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV. _h[electronic resource] |
| 260 |
_bBMC infectious diseases _c2014 |
||
| 300 |
_aS4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCoinfection _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV-1 _xphysiology |
| 650 | 0 | 4 |
_aHepacivirus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis C _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aAmadasi, Silvia | |
| 700 | 1 | _aCerini, Carlo | |
| 700 | 1 | _aGiralda, Mariarosaria | |
| 700 | 1 | _aNasta, Paola | |
| 700 | 1 | _aCastelli, Francesco | |
| 773 | 0 |
_tBMC infectious diseases _gvol. 14 Suppl 5 _gp. S4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1471-2334-14-S5-S4 _zAvailable from publisher's website |
| 999 |
_c24203972 _d24203972 |
||